See more : Check Point Software Technologies Ltd. (CHKP) Income Statement Analysis – Financial Results
Complete financial analysis of T&R Biofab Co., Ltd. (246710.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of T&R Biofab Co., Ltd., a leading company in the industry within the sector.
- Somboon Advance Technology Public Company Limited (SAT.BK) Income Statement Analysis – Financial Results
- Epsilon Energy Ltd. (EPSN) Income Statement Analysis – Financial Results
- Companhia de Gás de São Paulo – COMGÁS (CGAS3.SA) Income Statement Analysis – Financial Results
- PT Bumi Resources Minerals Tbk (BRMS.JK) Income Statement Analysis – Financial Results
- Coloplast A/S (CLPBY) Income Statement Analysis – Financial Results
T&R Biofab Co., Ltd. (246710.KQ)
Website: https://www.tnrbiofab.com
About T&R Biofab Co., Ltd.
T&R Biofab Co., Ltd. engages in the research and development of medical devices for transplantation and tissue regeneration in the areas of orthopedics, plastic surgery, and dentistry. It offers craniomaxillofacial meshes, dental meshes, and patient specific implants; and bioinks for 3D bioprinting and cell culture, stem cell research and delivery, and coating of scaffold and cultural dishes. The company was founded in 2013 and is based in Siheung-si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.20B | 5.75B | 3.23B | 6.81B | 1.29B |
| Cost of Revenue | 4.12B | 4.21B | 3.45B | 4.15B | 698.91M |
| Gross Profit | 1.08B | 1.54B | -212.49M | 2.66B | 588.21M |
| Gross Profit Ratio | 20.71% | 26.79% | -6.57% | 39.08% | 45.70% |
| Research & Development | 4.40B | 3.86B | 3.29B | 2.95B | 2.23B |
| General & Administrative | 1.01B | 863.75M | 646.87M | 527.32M | 172.67M |
| Selling & Marketing | 1.24B | 1.47B | 1.42B | 1.12B | 1.49B |
| SG&A | 2.25B | 2.34B | 2.06B | 1.65B | 4.42B |
| Other Expenses | 7.15B | -603.07M | -73.22B | -204.26M | 0.00 |
| Operating Expenses | 13.80B | 14.27B | 10.04B | 8.17B | 7.30B |
| Cost & Expenses | 17.92B | 18.48B | 13.49B | 12.31B | 8.00B |
| Interest Income | 1.67B | 1.20B | 463.61M | 245.22M | 506.97M |
| Interest Expense | 3.24M | 1.90M | 2.60B | 35.78M | 46.01M |
| Depreciation & Amortization | 2.16B | 1.95B | 1.74B | 1.27B | 814.37M |
| EBITDA | -11.26B | -10.96B | -65.72B | -4.30B | -6.05B |
| EBITDA Ratio | -216.56% | -190.50% | -2,504.58% | -64.48% | -469.67% |
| Operating Income | -12.72B | -12.90B | -10.25B | -5.51B | -6.86B |
| Operating Income Ratio | -244.73% | -224.13% | -316.91% | -80.95% | -532.94% |
| Total Other Income/Expenses | -695.16M | 775.42M | -59.82B | -95.37M | -185.33M |
| Income Before Tax | -13.42B | -10.34B | -70.07B | -5.60B | -6.25B |
| Income Before Tax Ratio | -258.10% | -179.63% | -2,166.15% | -82.36% | -485.66% |
| Income Tax Expense | 0.00 | -12.52M | -72.51B | -147.69M | 0.00 |
| Net Income | -13.42B | -10.34B | -70.07B | -5.60B | -6.25B |
| Net Income Ratio | -258.10% | -179.63% | -2,166.15% | -82.36% | -485.66% |
| EPS | -633.00 | -496.00 | -1.97K | -334.50 | -376.50 |
| EPS Diluted | -632.85 | -496.00 | -1.97K | -334.50 | -376.50 |
| Weighted Avg Shares Out | 21.20M | 20.84M | 35.57M | 16.75M | 16.60M |
| Weighted Avg Shares Out (Dil) | 21.20M | 20.84M | 35.57M | 16.75M | 16.60M |
Source: https://incomestatements.info
Category: Stock Reports